Effect of the addition of autologous serum
| Patient . | Response after weekly doses . | Best response after therapy . | Time to relapse, mo . | Site of relapse . | Salvage therapy . |
|---|---|---|---|---|---|
| 7 | PR | CR | 28 | Treated eye | Watchful waiting |
| 15 | PR | CR | 35+ | None | |
| 14 | SD | CR | 40+ | None | |
| 6 | SD | PR | 59+ | None | |
| 8 | SD | SD | 54+ | None* | |
| 11 | SD | SD | 44+ | None* | |
| 13 | SD | PD | 7 | Treated eye | Rituximab-bendamustine |
| 19 | SD | SD | 8 | Treated eye | Radiotherapy |
| 20 | SD | SD | 8 | Treated eye | Surgical resection |
| Patient . | Response after weekly doses . | Best response after therapy . | Time to relapse, mo . | Site of relapse . | Salvage therapy . |
|---|---|---|---|---|---|
| 7 | PR | CR | 28 | Treated eye | Watchful waiting |
| 15 | PR | CR | 35+ | None | |
| 14 | SD | CR | 40+ | None | |
| 6 | SD | PR | 59+ | None | |
| 8 | SD | SD | 54+ | None* | |
| 11 | SD | SD | 44+ | None* | |
| 13 | SD | PD | 7 | Treated eye | Rituximab-bendamustine |
| 19 | SD | SD | 8 | Treated eye | Radiotherapy |
| 20 | SD | SD | 8 | Treated eye | Surgical resection |
CR, complete remission; PD, progressive disease; PR, partial remission; SD, stable disease.
Patients 8 and 11 did not experience progressive disease after intralesional rituximab; however, they required palliative irradiation of the treated eye as a result of local symptoms after 4 and 22 months, respectively.